Literature DB >> 7679754

Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen.

T A Stamey1, D D Dietrick, M M Issa.   

Abstract

We present 3 of 25 patients with massive, occult transition zone cancers 7 to 86 cc in volume. Despite serum prostate specific antigen (PSA) levels of 150 to 456 ng./ml. (Yang polyclonal assay), all 3 were organ confined at radical prostatectomy and have undetectable serum PSA levels by an ultrasensitive assay at 300 to 650 days postoperatively. This clinical syndrome includes a highly elevated PSA level, benign prostatic hyperplasia on digital rectal examination, a nondiagnostic transrectal ultrasound and frequently negative transrectal or perineal needle biopsies. Clinical recognition of this syndrome plus systematic biopsies of the transition zone are the keys to diagnosis and potential cure of these patients. These cases may explain the 10% rate of men who present with metastatic prostate cancer and a normal rectal examination, much of the discrepancy between focal cancer on biopsy and large cancers in radical prostatectomy specimens, and why some men have an extraordinarily high serum PSA level and organ-confined cancer at prostatectomy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679754     DOI: 10.1016/s0022-5347(17)36131-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  [Transrectal ultrasound of the prostate. Current status and prospects].

Authors:  M Zacharias; K V Jenderka; H Heynemann; P Fornara
Journal:  Urologe A       Date:  2002-11       Impact factor: 0.639

2.  Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights.

Authors:  Ghazi Al Edwan; Sangeet Ghai; David Margel; Girish Kulkarni; Rob Hamilton; Ants Toi; Masoom A Haidar; Antonio Finelli; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

3.  Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians.

Authors:  R S Kirby; G Chisholm; C Chapple; C Hudd; M Swallow; D Shore
Journal:  J R Soc Med       Date:  1995-05       Impact factor: 5.344

4.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

5.  Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer.

Authors:  Ibrahim Karademir; Dinggang Shen; Yahui Peng; Shu Liao; Yulei Jiang; Ambereen Yousuf; Gregory Karczmar; Steffen Sammet; Shiyang Wang; Milica Medved; Tatjana Antic; Scott Eggener; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2013-11       Impact factor: 3.959

6.  Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group.

Authors:  G D Chisholm; S J Carne; J M Fitzpatrick; N J George; J C Gingell; J W Keen; R S Kirby; D Kirk; E P O'Donoghue; W B Peeling
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

Review 7.  The role of transrectal ultrasound in diagnosing prostate cancer.

Authors:  Richard Clements
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862

8.  Prognostic significance of prostate cancer originating from the transition zone.

Authors:  Christopher R King; Michelle Ferrari; James D Brooks
Journal:  Urol Oncol       Date:  2008-09-16       Impact factor: 2.954

9.  Giant organ confined prostatic adenocarcinoma: a case report.

Authors:  Jamin V Brahmbhatt; Louis S Liou
Journal:  J Med Case Rep       Date:  2008-01-29

10.  Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.

Authors:  Ming Yin; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-10-27       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.